We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Neurostimulation for the Relief of Acute Bronchoconstriction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00762931
Recruitment Status : Completed
First Posted : September 30, 2008
Last Update Posted : March 13, 2015
Information provided by (Responsible Party):

Study Description
Brief Summary:
The goal of this study is to validate design for the Resolve™ Stimulator and Proximity Electrode and the associated procedure to quickly and safely place an electrode into the neck, in the vicinity of the vagus nerve by a physician in either the Emergency Department or other appropriate hospital inpatient setting (e.g., ICU). The secondary goal is to confirm that the electrical signal being delivered via this electrode rapidly counters bronchoconstriction and improves airway flow.

Condition or disease Intervention/treatment Phase
Asthma Device: Neurostimulation Phase 2

Detailed Description:

The present study is to evaluate the safety of a new neurostimulator device, the Resolve Stimulator and Proximity Lead™, which comprises an external electrical signal generator coupled to temporary electrode that is percutaneously inserted in the neck.

Sponsor believes, based on animal testing data provided as well as consultations with physicians who regularly treat patients suffering from attacks of acute bronchoconstriction in ER and inpatient hospital settings, that this device could be used in the skilled care hospital setting to help rapidly relax the smooth muscle in the airway, relieving a clinically significant portion of the bronchoconstriction suffered by patients experiencing moderate to severe asthma attacks, allowing more effective delivery of inhaled medications to restore the patient to his or her baseline respiration status.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Neurostimulation for the Relief of Acute Bronchoconstriction
Study Start Date : September 2008
Primary Completion Date : September 2010
Study Completion Date : October 2010
Arms and Interventions

Arm Intervention/treatment
Experimental: Neurostimulation
All subjects will receive active treatment
Device: Neurostimulation
An electrical neurostimulation signal will be applied to the neck.
Other Name: ElectroCore Resolve Stimulator and Proximity Lead
Device: Neurostimulation
Subcutaneous lead placement for vagal nerve stimulation

Outcome Measures

Primary Outcome Measures :
  1. Validate design for the Stimulator and Electrode and the associated procedure to safely position it into the neck by a physician in either the Emergency Department or other appropriate hospital inpatient setting (e.g., ICU). [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. Improvement of common measures of breathing performance (FEV1). [ Time Frame: 30 minutes post treatment ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male / Female, Age 18-65
  • Subject declares a medical history of asthma or sufficient prior clinical experience/records exists to confirm the subject has received a diagnosis of bronchoconstriction
  • Completed >1 hrs of conventional breathing and related medication treatments without improvement in FEV1 to > 70% predicted
  • Able to give Informed Consent

Exclusion Criteria:

  • Scaring / abscess other problems with neck at electrode placement site
  • Known or suspected carotid artery disease (i.e. bruits or history of stenosis)
  • Suspected or confirmed coagulopathy
  • Suspected or confirmed sepsis
  • Irregular heart rate, rhythm
  • Receiving pressors to maintain blood pressure
  • Presently implanted electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant
  • Allergy to local anesthetics used for placement of the lead
  • History of lung cancer, emphysema, chronic obstructive pulmonary disease, or other comorbidity that might otherwise compromise the expected air flow volumes in the lungs
  • At risk of imminent respiratory collapse

    • Lung Function: FEV1 < 40% predicted
    • Signs and Symptoms: Extreme symptoms at rest, accessory muscle use, chest retraction
    • Alert State: Drowsy, confused
  • Treatment with anti-cholinergic medications within 4 hours of enrollment
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00762931

United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
United States, Minnesota
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415
United States, Missouri
Washington University School of Medicine, Barnes-Jewish Hospital,
St Louis, Missouri, United States, 63110
United States, Texas
Dorrington Medical Associates
Houston, Texas, United States, 77030
Sponsors and Collaborators
ElectroCore LLC
Study Director: JP Errico ElectroCore LLC
More Information

Responsible Party: ElectroCore LLC
ClinicalTrials.gov Identifier: NCT00762931     History of Changes
Other Study ID Numbers: BC-01
First Posted: September 30, 2008    Key Record Dates
Last Update Posted: March 13, 2015
Last Verified: March 2015

Keywords provided by ElectroCore LLC:
vagus nerve stimulation
vagal nerve stimulation
non invasive